Clinical evaluation of MRI in the diagnosis of borderline ovarian tumors.
OBJECTIVE
To evaluate the clinical potential of contrast-enhanced MRI with Gd-DTPA (gadopentetate dimeglumine) in the diagnosis of borderline ovarian tumors.


METHODS
Thirteen patients with 14 borderline ovarian tumors were evaluated with serum levels of four tumor markers (CA125, CA19-9, SLX and CEA) and contrast-enhanced MRI.


RESULTS
Among the 13 patients, five had normal serum levels of all four tumor markers, and five had high serum levels of plural tumor markers. The positive rates of CA125, CA19-9, SLX, and CEA were 46.2% (6/13), 38.5% (5/13), 30.8% (4/13), and 7.7% (1/13), respectively. With contrast-enhanced MRI, all 13 patients were diagnosed as having malignant tumors using the widely accepted criteria of MRI findings for the diagnosis of malignant ovarian tumors.


CONCLUSIONS
In the present study, all 14 borderline tumors had similar MRI findings to those of malignant tumors and were diagnosed as ovarian cancers with contrast-enhanced MRI, unrelated to the serum levels of tumor markers.
Takemori
Masayuki
M
Department of Obstetrics and Gynecology, Hyogo Medical Center for Adults, Akashi, Japan.
Nishimura
Ryuichiro
R
Hasegawa
Kazuo
K
D002288:Adenocarcinoma, Mucinous / Q000473:pathology* / Q000601:surgery; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000601:surgery; D010052:Ovariectomy; D011182:Postoperative Care; D011237:Predictive Value of Tests; D011300:Preoperative Care; D011379:Prognosis; D011856:Radiographic Image Enhancement; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D019786:Gadolinium DTPA